

---

# S&P TEST

SWOT & PESTLE.com

---

## VIATRIS SWOT & PESTLE ANALYSIS

© Barakaat Consulting - An Ezzy IT Consulting Business

This is a licensed product and is not to be photocopied or distributed. All rights reserved. Unauthorized reproduction is strictly prohibited. Research is based on best available materials and resources. Topurchase reprints of this document, please email [support@swotandpestle.com](mailto:support@swotandpestle.com).

**Company Name :** Viatris

**Company Sector :** Pharmaceuticals

**Operating Geography :** United States, North America, Global

**About the Company :**

Viatris is a global pharmaceutical company formed in 2020 through the merger of Mylan and Upjohn, a division of Pfizer. The company is headquartered in Pittsburgh, Pennsylvania, and has a presence in over 165 countries around the world. Viatris is focused on developing and manufacturing generic and branded pharmaceuticals, as well as over-the-counter medications, biosimilars, and complex generics. The company's portfolio includes treatments for a variety of medical conditions, including cardiovascular disease, diabetes, and respiratory illness. In addition to its pharmaceutical operations, Viatris is also committed to expanding access to healthcare and promoting sustainability. The company has partnerships with a variety of organizations to support healthcare initiatives and improve access to medications in underserved communities. Viatris has been included in the top 10% of a list of 800 global employers for 2022. As of early 2023, Viatris employed over 37,000 people.

The USP of Viatris lies in it being Viatris' one of the leading global healthcare companies. mission statement reads, "We act courageously and are uniquely positioned to be a source of stability in a world of evolving healthcare needs. Viatris empowers people worldwide to live healthier at every stage of life."

**Revenue :**

US\$ 16,218 million - FY ending 31st December 2022 (y-o-y decline 9%)

US\$ 17,886 million - FY ending 31st December 2021

## SWOT Analysis :

The SWOT Analysis for Viatris is given below:

Strengths	Weaknesses
<ol style="list-style-type: none"> <li>1.A global healthcare company catering to patients in more than 165 countries with 1400+ approved molecules.</li> <li>2.Strong and reliable supply chain.</li> <li>3.Viatris is the culmination of Mylan's strategic efforts and Upjohn's strong portfolio efforts.</li> <li>4.Continued and remarkable brand performance across all segments.</li> <li>5.Solid growth in Europe along with better revenue generation as compared to that from North America</li> </ol>	<ol style="list-style-type: none"> <li>1.Viatris employees involved in insider trading and securities fraud.</li> </ol>
Opportunities	Threats
<ol style="list-style-type: none"> <li>1.Viatris acquisitions last year are eyeing on becoming the global leader in eye care.</li> <li>2.Viatris is aiming towards growing beyond generics only player.</li> <li>3.Broadening the drug portfolio of Viatris across various geographies organically and through business development.</li> <li>4.Viatris is the leading drugmaker towards attaining production autonomy overseas.</li> </ol>	<ol style="list-style-type: none"> <li>1.Viatris's competitors are likely to raise drug prices in response to IRA.</li> <li>2.Legal battles for securing patents from competitors leads to delays in product launch.</li> <li>3.Competitor firm Thea Pharma gets FDA nod to launch a competitive product in the eye care segment.</li> </ol>

## PESTLE Analysis :

The PESTLE Analysis for Viatris is given below:

Political	Economical
1.Biden Administration Inflation Reduction Act (IRA) introduced to assist the government's Medicare health program.	1.Untamed inflation is the top concern of pharmaceutical industry. 2.Global cost cutting drive leading to huge layoffs
Social	Technological
1.Launching of Patient Assistance Program to provide certain medicines free of cost 2.Greedy pharma industries are minting profits but most Americans cannot afford buying medicines 3.Driving policy solutions for equitable access to medicines	1.Rise in expenditure on R&D in the US and China. 2.Artificial Intelligence is continuously the most disruptive emerging technological advancement every year.
Legal	Environmental
1.The Antitrust litigation filed to be settled by Viatris for \$264 million.	1.Focus on achieving emission reduction targets by Science Based Target initiative

Please note that our free summary reports contain the SWOT and PESTLE table contents only.

The complete report for **Viatris** SWOT & PESTLE Analysis is a paid report at **27 U.S.D.**



\* By clicking on "Buy Now" you agree to accept our "Terms and Conditions."



# S&P

SWOT & PESTLE.com

SWOT & PESTLE.com is a leading strategy research portal covering detailed Strengths, Weaknesses, Opportunities, Threats (SWOT) and Political, Economic, Social, Technological, Legal and Environmental (PESTLE) analysis of leading industry sectors and organizations across the globe. Our full and comprehensive collection on SWOT and PESTLE has been written by our team of professional analysts consisting of MBA's, CFA's and industry experts. Our analysis has helped businesses, researchers and scholars with valuable insights to make strategic decisions and take their research forward.

We at SWOT & PESTLE.com aim to aid the understanding of the multifaceted business world by presenting a list of diverse companies from across the globe. Business organizations today cannot function in ways that ignore the surroundings that they are set in. SWOT & PESTLE.com makes a keen observation into this aspect and accounts for factors affecting such businesses.

# Copyright Notice

The information provided in the SWOT and PESTLE research reports on [www.swotandpestle.com](http://www.swotandpestle.com) are from publicly available documents and sources which are deemed reliable. Further the reports contain analysis and views from the SWOT & PESTLE.com research and analyst team which consists of qualified experts. While every attempt has been made to ensure completeness, accuracy and reliability of the analysis, Barakaat Consulting and its associate websites cannot be held responsible or legal liable for omissions or errors in our reports or on any of our pages.

(C)2024 Barakaat Consulting. All rights reserved. This report may not be reproduced, copied or redistributed, in whole or in part, in any form or by any means, without the express written consent of Barakaat Consulting. Also, Barakaat Consulting is the sole copyright owner of this report, and any use of this report by any third party is strictly prohibited without a license expressly granted by Barakaat Consulting. Neither all nor any part of the contents of this report, or any opinions expressed herein, can be used in advertising, press releases, or promotional materials without prior written approval from Barakaat Consulting. Any violation of Barakaat Consultings rights in this report will be executed to the fullest extent of the law, including the pursuit of monetary damages and injunctive relief in the event of any breach of the foregoing restrictions.

Client Support:  
**[support@swotandpestle.com](mailto:support@swotandpestle.com)**